Faron Pharmaceuticals Oy
FARN.L · LSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 84.65 | 0.72 | -0.21 | -1.03 |
| FCF Yield | -10.58% | -10.25% | -12.44% | -14.01% |
| EV / EBITDA | -12,011.46 | -8.45 | -7.18 | -7.56 |
| Quality | ||||
| ROIC | -0.30% | 2,475.56% | -1,022.50% | -319.24% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.89 | 0.77 | 0.80 | 1.05 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | 3.06% | -2.36% | -3.02% | -28.78% |
| Safety | ||||
| Net Debt / EBITDA | -141.32 | -0.22 | -0.23 | 0.16 |
| Interest Coverage | 0.00 | 0.00 | -19.59 | -89.82 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |